Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2009-02-25
2011-12-06
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021400, C530S326000
Reexamination Certificate
active
08071548
ABSTRACT:
A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron is disclosed. The method comprises administering to the neuron an effective inhibiting amount of a peptide replacement agent for the NMDA receptor or neuronal protein interaction domain that effect said inhibition of the NMDA receptor-neuronal protein interaction. The method is of value in reducing the damaging effect of injury to mammalian cells. Postsynaptic density-95 protein (PSD-95) couples neuronal N-methyl-D-aspartate receptors (NMDARs) to pathways mediating excitotoxicity, ischemic and traumatic brain damage. This coupling was disrupted by transducing neurons with peptides that bind to modular domains on either side of the PSD-95/NMDAR interaction complex. This treatment attenuated downstream NMDAR signaling without blocking NMDAR activity, protected cultured cortical neurons from excitotoxic insults, dramatically reduced cerebral infarction volume in rats subjected to transient focal cerebral ischemia, and traumatic brain injury (TBI) in rats.
REFERENCES:
patent: 6911526 (2005-06-01), Sato et al.
patent: 6942981 (2005-09-01), Lu et al.
patent: 7432065 (2008-10-01), Lu et al.
patent: 7510824 (2009-03-01), Tymianski
patent: 7514224 (2009-04-01), Lu et al.
patent: 7595297 (2009-09-01), Tymianski
patent: 2002/0147306 (2002-10-01), Lin
patent: 2005/0037969 (2005-02-01), Lu et al.
patent: 2007/0161078 (2007-07-01), Lu et al.
patent: 2008/0274977 (2008-11-01), Belmares et al.
patent: 2009/0062213 (2009-03-01), Belmares et al.
patent: 2009/0131321 (2009-05-01), Tymianski
patent: 2009/0176713 (2009-07-01), Tymianski et al.
patent: 2273622 (2000-02-01), None
patent: WO 97/33173 (1997-09-01), None
patent: WO 00/69896 (2000-11-01), None
patent: WO 00/69897 (2000-11-01), None
patent: WO 01/57240 (2001-08-01), None
patent: WO 02/07751 (2002-01-01), None
Cui et al., Neurobiology of Disease, vol. 27, 2007, pp. 9901-9915.
Bassand et al. European J. Neuroscience, vol. 11, 1999, pp. 2031-2043.
Takagi et al., J. Neurochemistry, vol. 74, 2000, 169-178.
U.S. Appl. No. 09/584,555, filed May 31, 2000, Tymianski.
U.S. Appl. No. 12/557,884, filed Sep. 11, 2009, Tymianski.
Aarts et al., “Treatment of Ischemic Damage by Perturbing NMDA Receptor-PSD-95 Protein Interactions,”Science, 298:846-850 (2002).
Arundine et al., “Enhanced Vulnerability to NMDA Toxicity in Sublethal Traumantic Neuronal Injury In Vitro,”Journal of Neurotrauma, 20(12):1377-1396 (2003).
Arundine et al., “Glutamatergic Mechanisms of Isolated Secondary Traumatic Neuronal Injury in Vitro”,Society for Neuroscience Abstracts, 27(1):569, (2001).
Beal, “Mechanisms of excitoxicity in neurologic diseases”FASEB J., 6:3338-3344 (1992).
Bezprozvanny et al., “Classification of PDZ domains,”FEBS Letters, 509:457-462 (2001).
Branswell, “New stroke drug shows promise in animal trials”CTV.ca, Canadian Press (ca. Oct. 25, 2002).
Brenman et al., “Cloning and Characterization of Postsynaptic Density 93, a Nitric Oxide Synthase Interacting Protein,”J. Neuroscience, 16(23):7407-7415 (1996).
Buchan et al., “Failure to prevent selected CA1 neuronal death and reduce cortical infarction following cerebral ischemia with inhibition of nitric oxide synthase”Neuroscience61(1):1-11 (1994).
Cheng et al., “Structure-based maximal affinity model predicts small-molecule druggability”,Nature Biotech., 25(1):71-75, (2007).
Christopherson et al., “PSD-95 Assembles a Ternary Complex withN-Methyl-D-aspartic Acid Receptor and a Bivalent Neuronal NO Synthase PDZ Domain,”J. Biol. Chem., 274(39):27467-27473 (1999).
Cohen et al., “Binding of the inward rectifier K+ channel Kir 2.3 to PSD-95 is regulated by protein kinase A phosphorylation,”Neuron, 17(4):759-767 (1996).
Cregan et al., “[(S)-Alpha-Phenyl-2-Pyridine-Ethanamine Dihydrochloride], A Low Affinity Uncompetitive N-Methyl-D-Aspartic Acid Antagonist, is Effective in Rodent Models of Global and Focal Ischemia,”J. Pharm. Exp. Therap., 283(3):1412-1424 (1997).
Davis et al., “Termination of acute stroke studies involving Selfotel treatment”The Lancet, 349:32 (1997).
Davis et al., “Selfotel in Acute Ischemic Stroke Possible Neurotoxic Effects of an NMDA Antagonist,”Stroke, 31:347-354 (2000).
Dawson et al., “Inhibition of nitric oxide synthesis does not reduce infarct volume in a rat model of focal cerebral ischaemia”Neurosci., Lett. 142:151-154 (1992).
Dotinga, “Synthetic protein protects rats from stroke” Healthcentral (Oct. 24, 2002).
Doyle et al., “Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ,”Cell, 85(7):1067-1076 (1996).
Dyker et al., “Safety and tolerability study of Aptiganel Hydrochloride in patients with an acute ischemic stroke”Stroke30:2038-2042 (1999).
El-Maghrabi et al., “Saturable binding of halothane to rat brain synaptosomes,”PNAS, 89:4329-4332 (1992).
Excerpt entitled: “New stroke drug may limit brain damage,”Canadian Press(Oct. 25, 2002).
Excerpt entitled: “New drug prevents brain damage from stroke” Discoveryhealth.com (Oct. 25, 2002).
Excerpt entitled: “Stroke solutions”CBC Radio One(Oct. 25, 2002).
Excerpt entitled “A gentler treatment for stroke”Science, 298:699-701 (Oct. 25, 2002).
Excerpt entitled: “Researchers prevent cell death in rats with stroke”HeartCenterOnline for Patients™ (Oct. 25, 2002).
Fang et al., “Synaptic PDZ Domain-mediated Protein Interactions Are Disrupted by Inhalational Anesthetics,”J. Biol. Chem., 278(30):36669-36675 (2003).
Ferrer-Montiel et al., “Selected peptides targeted to the NMDA receptor channel protect neurons from excitotoxic death,”Nature Biotechnology, 16(3):286-291 (1998).
Fix et al., “Neuronal Vacuolization and Necrosis Induced by the NoncompetitiveN-methyl-D-asparate (NMDA) Antagonist MK(+)801 (Dizocilpine Maleate): A Light and Electron Microscope Evaluation of the Rat Retrospinal Cortex,”Experimental Neurology, 123:204-215 (1993).
Ford et al., “Protein transduction: an alternative to genetic intervention?”,Gene Therapy8:1-4 (2001).
Frankel et al., “Cellular Uptake of the Tat Protein from Human Immunodeficiency Virus”,Cell, 55:1189-1193, (1988).
Fuh et al., “Analysis of PDZ Domain-Ligand Interactions Using Carboxyl-terminal Phage Display,”J. Biol. Chem., 275(28):21486-21491 (2000).
Gee et al., “Single-amino acid substitutions alter the specificity and affinity of PDZ domains for their ligands,”Biochemistry, 39(47):14638-14646 (2000).
Grotta et al., “Safety and tolerability of the Glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke”Stroke, 26:602-605 (1995).
Harris et al., “Mechanism and role of PDZ domains in signaling complex assembly,”J. Cell Science, 114:3219-3231 (2001).
Hayman et al., “Neurotoxicity of Peptide Analogues of the Transactivating Protein tat from Maedi-Visna Virus and Human Immunodeficiency Virus”,Neuroscience, 53(1):1-6, (1993).
Hirbec et al., “The PDZ Proteins PICK1, GRIP, and Syntenin Bind Multiple Glutamate Receptor Subtypes,”J. Biol. Chem., 277(18):15221-15224 (2002).
Horio et al., “Clustering and Enhanced Activity of an Inwardly Rectifying Potassium Channel, Kir4.1, by an Anchoring Protein, PSD-95/SAP90,”J. Biol. Chem., 272(20):12885-12888 (1997).
Hsueh et al., “Disulfide-Linked Head-to-Head Multimerization in the Mechanism of Ion Channel Clustering by PSD-95,”Neuron, 18:803-814 (1997).
Hu et al., “β1-Adrenergic Receptor Association with PSD-95,”J. Biol. Chem., 275(49):38659-38666 (2000).
Hudzik et al., “Effects of anticonvulsants in a novel operant learning paradigm in rats: C
Alston and Bird LLP
Gucker Stephen
Kolker Daniel E
NoNo, Inc.
LandOfFree
Method of reducing injury to mammalian cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of reducing injury to mammalian cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of reducing injury to mammalian cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4263792